retatrutide glp-1 gip glucagon agonist Retatrutide, a GIP, and receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA GLP-1 Medications for Weight Loss:

and S.R.G

Data availability The datasets utilized and/or analyzed in this study are available from the corresponding author upon reasonable request

Compounded semaglutide is a custom-prepared version of the same active ingredient found in Ozempic and Wegovy, both registered trademarks of Novo Nordisk A/S, but it's prepared by a licensed compounding pharmacy rather than manufactured by Novo Nordisk

Hu Y, Zheng S-L, Ye X-L, et al

This reconstitution guide is for educational purposes only

A meta-analysis of 45 clinical trials including 52,600 patients found no statistically significant increased risk of thyroid cancer in GLP-1 receptor agonist users